Pharmaceuticals, Biotechnology and Life Sciences
Pharmaceutical company Adalvo today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Livogiva, indicated for use in postmenopausal women with osteoporosis who are at high risk of having bone fractures.
Alvogen announced today the completion of the sale of its Central and Eastern European (CEE) business to Zentiva for an undisclosed value. The sale of the company’s CEE platform includes over 200 generic and over-the-counter products across multiple therapeutic areas and covering 14 key markets.
Alvogen is selling its Central and Eastern European business to Zentiva, for an undisclosed amount, to focus on developing other areas, with the transaction to be closed in first quarter of 2020.
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement regarding Celgene’s (NASDAQ:CELG) settlement with Lotus Pharmaceutical Co., Ltd.…
Alvogen licensed to sell volume-limited amounts of generic lenalidomide in the U.S. beginning on a confidential date after the March…
@alvogenpr subsidiary in Taiwan, Lotus Pharmaceuticals today announced capital and business collaboration agreements with Fuji Pharma in Japan, as Fuji has acquired a 2.0% stake in Lotus for approximately US$20 million (or NT$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.
Alvogen has launched its generic equivalent to Indivior UK LLC’s Suboxone sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the U.S.
Alvotech has raised $300 million through a private bond offering to fuel continued growth, refinance of existing debt and the further development of Alvotech’s biosimilar assets.
Alvogen’s Chairman & CEO Robert Wessman is the new Chairman of the Board at the publicly listed Lotus Pharmaceuticals in Taiwan, succeeding Andrew Lin. Lotus Pharmaceuticals, which is majority-owned by Alvogen, has been under the leadership and guidance of Lin since 2016.
Alvogen and Prestige BioPharma have entered into a deal for the exclusive partnership and supply for the commercialization of Prestige…